Glovers act for Silence Therapeutics

Glovers’ Commercial Property Partner Philip Mundy has acted for new client Silence Therapeutics Plc in connection with the lease of their new London corporate headquarters at  the Harrods owned Crown House office building in Kensington Olympia.

Silence Therapeutics is a leading drug development company. Listed on the Alternative Investment Market, its technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells. This, in turn, allows the development of therapeutics for diseases with high unmet clinical need. Silence Therapeutics’ technology is currently in the clinic in a Phase 2a pancreatic cancer trial.

Kinney Green advised Silence Therapeutics on the agency side.

For further information, please contact Philip Mundy at